Sung-Bau Lee

Prof. Dr. Sung-Bau Lee


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
SLSung-Bau Lee
Sung-Bau Lee
SSSandra Segura-Bayona
Sandra Segura-Bayona
MVMarina Villamor-Payà
Marina Villamor-Payà
GSGiulia Saredi
Giulia Saredi
MTMatthew A. M. Todd
Matthew A. M. Todd
AGAnja Groth
Anja Groth
DNA sequence and epigenetic information embedded in chromatin must be faithfully duplicated and transmitted to daughter cells during cell division. However, how chromatin assembly and DNA replication are integrated remains unclear. We examined the contribution of the Tousled-like kinases 1 and 2 (TLK1/TLK2) to chromatin assembly and maintenance of replication fork integrity. We show that TLK activity is required for DNA replication and replication-coupled nucleosome assembly and that lack of TLK activity leads to replication fork stalling and the accumulation of single-stranded DNA, a phenotype distinct from ASF1 depletion. Consistent with these results, sustained TLK depletion gives rise to replication-dependent DNA damage and p53-dependent cell cycle arrest in G1. We find that deficient replication-coupled de novo nucleosome assembly renders replication forks unstable and highly dependent on the ATR and CHK1 checkpoint kinases, as well as poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) activity, to avoid collapse. Human cancer data revealed frequent up-regulation of TLK genes and an association with poor patient outcome in multiple types of cancer, and depletion of TLK activity leads to increased replication stress and DNA damage in a panel of cancer cells. Our results reveal a critical role for TLKs in chromatin replication and suppression of replication stress and identify a synergistic lethal relationship with checkpoint signaling and PARP that could be exploited in treatment of a broad range of cancers.

1 June 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KNKunal Nepali
Kunal Nepali
TCTing-Yu Chang
Ting-Yu Chang
MLMei-Jung Lai
Mei-Jung Lai
KHKai-Cheng Hsu
Kai-Cheng Hsu
YYYun Yen
Yun Yen
JLJing-Ping Liou
Jing-Ping Liou

1 April 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASArshdeep Singh
Arshdeep Singh
TCTing-Yu Chang
Ting-Yu Chang
NKNavdeep Kaur
Navdeep Kaur
KHKai-Cheng Hsu
Kai-Cheng Hsu
YYYun Yen
Yun Yen
JLJing-Ping Liou
Jing-Ping Liou

16 December 2021 in Life
Verified
Journal Article
Open access
PDF file
HLHung-Yu Lin
Hung-Yu Lin
YLYong-Shiou Lin
Yong-Shiou Lin
SSShou-Ping Shih
Shou-Ping Shih
SLSung-Bau Lee
Sung-Bau Lee
Mohamed El-ShazlyMohamed El-Shazly
Mohamed El-Shazly
MLMei-Chin Lu
Mei-Chin Lu
Many active substances from marine organisms are produced by symbiotic microorganisms such as bacteria, fungi, and algae. Secondary metabolites from marine actinomycetes exhibited several biological activities and provided interesting drug leads. This study reported the isolation of Lu01-M, a secondary metabolite from the marine actinomycetes Streptomyces sp., with potent anti-proliferative activity against prostate cancers. Lu01-M blocked cell proliferation with IC50 values of 1.03 ± 0.31, 2.12 ± 0.38, 1.27 ± 0.25 μg/mL in human prostate cancer PC3, DU145, and LNCaP cells, respectively. Lu01-M induced cytotoxic activity through multiple mechanisms including cell apoptosis, necroptosis, autophagy, ER stress, and inhibiting colony formation and cell migration. Lu01-M induced cell cycle arrest at the G2/M phase and DNA damage. However, the activity of autophagy induced survival response in cancer cells. Our findings suggested that Lu01-M holds the potential to be developed as an anti-cancer agent against prostate cancers.

1 June 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
INIin Narwanti
Iin Narwanti
ZYZih-Yao Yu
Zih-Yao Yu
BSBidyadhar Sethy
Bidyadhar Sethy
MLMei-Jung Lai
Mei-Jung Lai
HLHsueh-Yun Lee
Hsueh-Yun Lee
JLJing-Ping Liou
Jing-Ping Liou

22 October 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TCTing-Yu Chang
Ting-Yu Chang
YYYan Yan
Yan Yan
ZYZih-Yao Yu
Zih-Yao Yu
MRMoeez Rathore
Moeez Rathore
NLNian-Zhe Lee
Nian-Zhe Lee
SLSung-Bau Lee
Sung-Bau Lee
The elevated level of replication stress is an intrinsic characteristic of cancer cells. Targeting the mechanisms that maintain genome stability to further increase replication stress and thus induce severe genome instability has become a promising approach for cancer treatment. Here, we identify histone deacetylase 8 (HDAC8) as a drug target whose inactivation synergized with the inhibition of checkpoint kinases to elicit substantial replication stress and compromise genome integrity selectively in cancer cells. We showed that simultaneous inhibition of HDAC8 and checkpoint kinases led to extensive replication fork collapse, irreversible cell-cycle arrest, and synergistic vulnerability in various cancer cells. The efficacy of the combination treatment was further validated in patient tumor–derived organoid (PDO) and xenograft mouse (PDX) models, providing important insights into patient-specific drug responses. Our data revealed that HDAC8 activity was essential for reducing the acetylation level of structural maintenance of chromosomes protein 3 (SMC3) ahead of replication forks and preventing R loop formation. HDAC8 inactivation resulted in slowed fork progression and checkpoint kinase activation. Our findings indicate that HDAC8 guards the integrity of the replicating genome, and the cancer-specific synthetic lethality between HDAC8 and checkpoint kinases provides a promising replication stress–targeting strategy for treating a broad range of cancers.